{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:35:28Z","timestamp":1761766528329,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T00:00:00Z","timestamp":1553558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40261-019-00778-5","type":"journal-article","created":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T07:02:23Z","timestamp":1553583743000},"page":"577-583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Sunitinib Rechallenge After Other Targeted Therapies in Metastatic Renal Cell Carcinoma Patients: A Single-Center, Retrospective Study"],"prefix":"10.1007","volume":"39","author":[{"given":"Kriszti\u00e1n","family":"Nagyiv\u00e1nyi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9411-9202","authenticated-orcid":false,"given":"Barna","family":"Budai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fruzsina","family":"Gyergyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zs\u00f3fia","family":"K\u00fcronya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krisztina","family":"B\u00edr\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lajos","family":"G\u00e9czi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,26]]},"reference":[{"key":"778_CR1","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/MOU.0000000000000206","volume":"25","author":"S Oudard","year":"2015","unstructured":"Oudard S, Vano Y. The role of rechallenge with targeted therapies in metastatic renal-cell carcinoma. Curr Opin Urol. 2015;25:402\u201310.","journal-title":"Curr Opin Urol."},{"key":"778_CR2","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology\u2014Kidney cancer. \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf\n                    \n                  . Accessed 7 Sep 2018."},{"key":"778_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15586\/jkcvhl.2014.7","volume":"1","author":"C Morais","year":"2014","unstructured":"Morais C. Sunitinib resistance in renal cell carcinoma. J Kidney Cancer VHL. 2014;1:1\u201311.","journal-title":"J Kidney Cancer VHL."},{"key":"778_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/1756287217713902","volume":"9","author":"M Rizzo","year":"2017","unstructured":"Rizzo M, Porta C. Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence. Ther Adv Urol. 2017;9:195\u2013207.","journal-title":"Ther Adv Urol."},{"issue":"suppl 5","key":"778_CR5","doi-asserted-by":"publisher","first-page":"v58","DOI":"10.1093\/annonc\/mdw328","volume":"27","author":"B Escudier","year":"2016","unstructured":"Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v58\u201368.","journal-title":"Ann Oncol."},{"key":"778_CR6","doi-asserted-by":"publisher","unstructured":"Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019; \n                    https:\/\/doi.org\/10.1093\/annonc\/mdz056\n                    \n                  .","DOI":"10.1093\/annonc\/mdz056"},{"key":"778_CR7","doi-asserted-by":"publisher","unstructured":"Nagyiv\u00e1nyi K, B\u00edr\u00f3 K, Gyergyay F, K\u00fcronya Z, N\u00e9meth H, G\u00e9czi L. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Ann Oncol. 2012;23(Suppl 9):abstract 849P. \n                    https:\/\/doi.org\/10.1093\/annonc\/mds399\n                    \n                  .","DOI":"10.1093\/annonc\/mds399"},{"key":"778_CR8","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/bjc.2014.214","volume":"111","author":"C Porta","year":"2014","unstructured":"Porta C, Paglino C, Gr\u00fcnwald V. Sunitinib re-challenge in advanced renal-cell carcinoma. Br J Cancer. 2014;111:1047\u201353.","journal-title":"Br J Cancer."},{"key":"778_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejca.2016.04.003","volume":"62","author":"S Oudard","year":"2016","unstructured":"Oudard S, Geoffrois L, Guillot A, Chevreau C, Deville JL, Falkowski S, et al. Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study. Eur J Cancer. 2016;62:28\u201335.","journal-title":"Eur J Cancer."},{"key":"778_CR10","doi-asserted-by":"publisher","first-page":"5400","DOI":"10.1002\/cncr.25583","volume":"116","author":"IN Zama","year":"2010","unstructured":"Zama IN, Hutson TE, Elson P, Cleary JM, Choueiri TK, Heng DY, et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer. 2010;116:5400\u20136.","journal-title":"Cancer."},{"key":"778_CR11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1159\/000328575","volume":"34","author":"V Gr\u00fcnwald","year":"2011","unstructured":"Gr\u00fcnwald V, Weikert S, Seidel C, Busch J, Johannsen A, Fenner M, et al. Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC. Onkologie. 2011;34:310\u20134.","journal-title":"Onkologie."},{"key":"778_CR12","doi-asserted-by":"publisher","first-page":"e525","DOI":"10.1016\/j.clgc.2016.04.009","volume":"14","author":"A Daste","year":"2016","unstructured":"Daste A, Gross-Goupil M, Quivy A, Fran\u00e7ois L, Bernhard JC, Ravaud A. Efficacy of rechallenge of metastatic renal cell carcinoma patient with sunitinib after prior resistance to axitinib: case report and review of the literature. Clin Genitourin Cancer. 2016;14:e525\u20137.","journal-title":"Clin Genitourin Cancer."},{"key":"778_CR13","first-page":"201","volume":"61","author":"A Yoshinaga","year":"2015","unstructured":"Yoshinaga A, Kamata S. Efficacy of sunitinib rechallenge in metastatic renal cell carcinoma: a case report. Hinyokika Kiyo. 2015;61:201\u20135.","journal-title":"Hinyokika Kiyo."},{"key":"778_CR14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/annonc\/mdp548","volume":"21","author":"A Ravaud","year":"2010","unstructured":"Ravaud A, Digue L, Trufflandier N, Smith D. VEGFR TKI \u2018resistance\u2019 or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma. Ann Oncol. 2010;21:431\u20132.","journal-title":"Ann Oncol."},{"key":"778_CR15","doi-asserted-by":"crossref","unstructured":"Porta C, Ferrari VD, Zucali PA, Fornarini G, Bernardo A, Falconeri A, et al. Prospective phase II study of sunitinib rechallenge in metastatic renal cell carcinoma (mRCC): A G.I.O.N. trial. J Clin Oncol. 2017;35(15 suppl):e16081.","DOI":"10.1200\/JCO.2017.35.15_suppl.e16081"},{"key":"778_CR16","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00432-014-1610-x","volume":"140","author":"L Maute","year":"2014","unstructured":"Maute L, Gr\u00fcnwald V, Weikert S, Kube U, Gauler T, Kahl C, et al. Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis. J Cancer Res Clin Oncol. 2014;140:823\u20137.","journal-title":"J Cancer Res Clin Oncol."},{"key":"778_CR17","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1080\/14737140.2017.1390432","volume":"17","author":"F Felicetti","year":"2017","unstructured":"Felicetti F, Nervo A, Piovesan A, Berardelli R, Marchisio F, Gallo M, et al. Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer. Expert Rev Anticancer Ther. 2017;17:1093\u20138.","journal-title":"Expert Rev Anticancer Ther."},{"key":"778_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s12253-017-0345-9","volume":"25","author":"K Nagyiv\u00e1nyi","year":"2019","unstructured":"Nagyiv\u00e1nyi K, Budai B, K\u00fcronya Z, Gyergyay F, B\u00edr\u00f3 K, Bodrogi I, et al. Outcome of restarted sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective trial and combined case reports from literature. Pathol Oncol Res. 2019;25:241\u20137.","journal-title":"Pathol Oncol Res."},{"key":"778_CR19","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1016\/j.ejca.2014.03.012","volume":"50","author":"S N\u00e9grier","year":"2014","unstructured":"N\u00e9grier S, Bushmakin AG, Cappelleri JC, Korytowsky B, Sandin R, Charbonneau C, et al. Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma. Eur J Cancer. 2014;50:1766\u201371.","journal-title":"Eur J Cancer."},{"key":"778_CR20","doi-asserted-by":"publisher","first-page":"396","DOI":"10.20517\/2394-4722.2016.27","volume":"2","author":"E Gonzalez","year":"2016","unstructured":"Gonzalez E, Alfaro S, Ramos-Esquivel A, Landaverde DU. Sunitinib effectiveness and safety as first line treatment in metastatic renal cell carcinoma, in the Costa Rican population. J Cancer Metastasis Treat. 2016;2:396\u2013401.","journal-title":"J Cancer Metastasis Treat."},{"key":"778_CR21","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.clgc.2015.11.016","volume":"14","author":"K Nagyiv\u00e1nyi","year":"2016","unstructured":"Nagyiv\u00e1nyi K, Budai B, B\u00edr\u00f3 K, Gyergyay F, Noszek L, K\u00fcronya Z, et al. Synergistic survival: a new phenomenon connected to adverse events of first-line sunitinib treatment in advanced renal cell carcinoma. Clin Genitourin Cancer. 2016;14:314\u201322.","journal-title":"Clin Genitourin Cancer"},{"key":"778_CR22","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1016\/j.clgc.2016.04.021","volume":"14","author":"M Arta\u00e7","year":"2016","unstructured":"Arta\u00e7 M, \u00c7o\u015fkun H\u015e, Korkmaz L, Ko\u00e7er M, Turhal NS, Engin H, et al. Using interferon alfa before tyrosine kinase inhibitors may increase survival in patients with metastatic renal cell carcinoma: a Turkish Oncology Group (TOG) study. Clin Genitourin Cancer. 2016;14:e347\u201353.","journal-title":"Clin Genitourin Cancer"},{"key":"778_CR23","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.ctrv.2012.01.003","volume":"38","author":"A Ravaud","year":"2012","unstructured":"Ravaud A, Gross-Goupil M. Overcoming resistance to tyrosine kinase inhibitors in renal cell carcinoma. Cancer Treat Rev. 2012;38:996\u20131003.","journal-title":"Cancer Treat Rev."},{"key":"778_CR24","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.14694\/EdBook_AM.2014.34.e228","volume":"2014","author":"M Schmidinger","year":"2014","unstructured":"Schmidinger M. Improving outcomes in metastatic clear cell renal cell carcinoma by sequencing therapy. Am Soc Clin Oncol Educ Book. 2014;2014:e228\u201338.","journal-title":"Am Soc Clin Oncol Educ Book."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00778-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-019-00778-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00778-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T00:08:02Z","timestamp":1585094882000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-019-00778-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,26]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["778"],"URL":"https:\/\/doi.org\/10.1007\/s40261-019-00778-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2019,3,26]]},"assertion":[{"value":"26 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No source of funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Kriszti\u00e1n Nagyiv\u00e1nyi, Barna Budai, Fruzsina Gyergyay, Zs\u00f3fia K\u00fcronya, Krisztina B\u00edr\u00f3 and Lajos G\u00e9czi declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures in this study were in accordance with the 1964 Helsinki declaration (and its amendments). The Ethical Committee of the institute and the Hungarian Medical Research Council approved the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not required for this retrospective study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}